By David Cassak
A decade ago, when the financing of medical device start-ups became nearly impossible—when public investors fled from the sector after...
Synecor's Golden Touch
Device incubator Synecor has solved one of the most taxing problems incubators face-an adequate financing model-with a string of deals as impressive as the technology it has launched.
More from Business Strategy
More from In Vivo
• By
Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.
• By
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.
• By
While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.